RxDoctor Payments Data

Jill Welker, PA

Physician Assistant · Murfreesboro, TNNPI 1871866376

Payments from drug & device makers

$7,570in general payments, 2019–2025

Across 403 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$727
  • Pfizer$608
  • Biohaven Pharmaceutical Holding Company Ltd.$608
  • Lilly USA, LLC$495
  • Otsuka America Pharmaceutical, Inc.$424
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$3545%
  • Food & beverage$7,21695%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,570 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$55,945
Medicare patients
318
Services billed
1,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$38,108
JardianceEmpagliflozin22$27,223
FarxigaDapagliflozin Propanediol19$23,583
TrulicityDulaglutide11$19,570
LamictalLamotrigine22$17,095
MyrbetriqMirabegron14$9,726
Breo ElliptaFluticasone/Vilanterol13$5,266
Atorvastatin Calcium100$1,223
Levothyroxine Sodium119$988
Tamsulosin Hcl50$828
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide12$727
Duloxetine Hcl31$680
Albuterol Sulfate HfaAlbuterol Sulfate42$677
Omeprazole38$622
Lisinopril70$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$727$38,10817 claims
Boehringer IngelheimJardiance$173$27,22322 claims
AstraZenecaFarxiga$165$23,58319 claims
GSKLamictal, Breo Ellipta$375$22,36035 claims
Lilly USA, LLCTrulicity$495$19,57011 claims
Astellas Pharma US IncMyrbetriq$135$9,72614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →